SAN DIEGO and PENNINGTON, N.J., Nov.
5, 2018 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer
immunotherapies, today announced that it will host a live
conference call on Tuesday, November
6, 2018 at 8:30 a.m. ET.
During the conference call, OncoSec's leadership will review
preliminary clinical and immunological data from its ongoing
registration-directed KEYNOTE-695 study. KEYNOTE-695 is a global,
multicenter, registration-directed Phase 2b trial of TAVO™ (intratumoral tavokinogene
telseplasmid/IL-12) in combination with intravenous pembrolizumab
(KEYTRUDA®), in patients with Stage III/IV metastatic melanoma who
have definitively failed FDA approved anti-PD-1 treatments,
pembrolizumab and/or nivolumab (OPDIVO®).
The conference call will be accessible by dialing 1-844-562-3893
(domestic) or 1-409-220-9946 (international) and referring to
conference ID 7767858. An accompanying presentation will be
referenced during the conference call and can be accessed under
"Events and Presentations" in the Investors section of OncoSec's
website at ir.oncosec.com. A replay of the webcast will
be available shortly after the conference call and will be
available for 30 days following the call.
Data from KEYNOTE-695 will also be presented at The Society for
Immunotherapy of Cancer (SITC) Annual Meeting taking place on
November 7-11, 2018 in Washington, D.C.
About OncoSec Medical Incorporated
OncoSec is a clinical-stage biotechnology company focused on
developing cytokine-based intratumoral immunotherapies to stimulate
the body's immune system to target and attack cancer.
OncoSec's lead immunotherapy platform – TAVO™ (tavokinogene
telseplasmid) – enables the intratumoral delivery of DNA-based
interleukin-12 (IL-12), a naturally occurring protein with
immune-stimulating functions. The technology, which employs
electroporation, is designed to produce a controlled, localized
expression of IL-12 in the tumor microenvironment, enabling the
immune system to target and attack tumors throughout the
body. OncoSec has built a deep and diverse clinical pipeline
utilizing TAVO™ as a potential treatment for multiple cancer
indications either as a monotherapy or in combination with leading
checkpoint inhibitors; with the latter potentially enabling OncoSec
to address a great unmet medical need in oncology: anti-PD-1
non-responders. Results from recently completed
clinical studies of TAVO™ have demonstrated a local immune
response, and subsequently, a systemic effect as either a
monotherapy or combination treatment approach. In
addition to TAVO™, OncoSec is identifying and developing new
DNA-encoded therapeutic candidates and tumor indications for use
with its ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc.
OPDIVO® are registered trademarks of Bristol-Myers Squibb
Company.
ImmunoPulse® is a registered trademark of OncoSec Medical
Incorporated.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
David Schemelia / Jason Rando
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
dschemelia@tiberend.com
jrando@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-host-conference-call-to-review-preliminary-keynote-695-data-300743767.html
SOURCE OncoSec Medical Incorporated